Advancing Therapies in Benign Prostatic Hyperplasia
Christopher E. Kelly, MD, discusses how emerging pharmaceutical interventions, minimally invasive surgical techniques, and personalized treatment strategies revolutionize management approaches for benign prostatic hyperplasia. He focuses on improving patient outcomes, reducing adverse effects, and addressing the complex symptomatology of this common age-related urological condition.
EP. 1: BPH: The Patient Journey
March 31st 2025A panelist discusses how benign prostatic hyperplasia (BPH) management involves a comprehensive patient journey that encompasses initial diagnostic evaluation, tailored pharmacological interventions including α-blockers and 5-α reductase inhibitors, and a progressive treatment approach ranging from conservative drug therapy to potential surgical options based on symptom severity and patient response.
EP. 2: Resective Surgery and Minimally Invasive Procedures For BPH
April 14th 2025A panelist discusses how benign prostatic hyperplasia (BPH) treatment has evolved to include a spectrum of minimally invasive and surgical interventions, ranging from emerging technologies like prostatic urethral lift (PUL) and water vapor thermal therapy (WVTT) to more established resective surgical techniques such as transurethral resection of the prostate (TURP), holmium laser enucleation (HoLEP), Aquablation, and Greenlight XPS, providing urologists with a diverse array of options tailored to individual patient characteristics, prostate size, and specific clinical needs.
